Cardlytics (CDLX) CFO lists 117,930-share stake in Form 3 SEC filing

Rhea-AI Filing Summary

Cardlytics, Inc. filed a Form 3 showing its new Chief Financial Officer, Evans David Thomas, as a beneficial owner of company stock. As of the event date of January 12, 2026, he beneficially owns 117,930 shares of Cardlytics common stock held directly. The filing does not list any derivative securities such as options or warrants. This establishes his initial reportable ownership position as an officer of the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Evans David Thomas

Role Chief Financial Officer

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 117,930 shares (Direct)

Footnotes (1)

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Evans David Thomas

(Last) (First) (Middle)

C/O CARDLYTICS, INC.

675 PONCE DE LEON AVENUE NE, SUITE 4100

(Street)

ATLANTA GA 30308

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/12/2026

3. Issuer Name and Ticker or Trading Symbol
Cardlytics, Inc. [ CDLX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	117,930	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney

	/s/ Nick Lynton, Attorney-in-Fact	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the latest Form 3 filing for CDLX disclose?

The Form 3 discloses that Cardlytics, Inc. Chief Financial Officer Evans David Thomas beneficially owns 117,930 shares of the companys common stock as of January 12, 2026.

How many Cardlytics (CDLX) shares does CFO Evans David Thomas own?

CFO Evans David Thomas beneficially owns 117,930 shares of Cardlytics common stock, according to the Form 3.

Are the CDLX shares held directly or indirectly by the CFO?

The Form 3 indicates the 117,930 Cardlytics common shares are held directly by Evans David Thomas, with no indirect ownership reported.

Does the Cardlytics CFO report any derivative securities on this Form 3?

No derivative securities are listed; the Form 3 only reports beneficial ownership of 117,930 shares of common stock and shows no options, warrants, or other derivatives.

What is the event date for the Cardlytics (CDLX) Form 3 ownership report?

The event date requiring the Form 3 statement is January 12, 2026.

What is the role of the reporting person in the Cardlytics Form 3?

The reporting person, Evans David Thomas, is identified as the Chief Financial Officer of Cardlytics, Inc.